Abstract

ROLE OF MIFEPRISTONE IN THE TREATMENT OF UTERINE FIBROID

Nidhi Patel, Wansalan Karu Shullai* and Garima

Abstract

AIM: To assess safety and efficacy of Mifepristone (50 mg daily for 6 months) on fibroid size, endometrium and symtoms related to fibroid. Material and method: Study was carried out in Sir Sunderlal Hospital BHU. 55 patients were randomly assigned into two groups: group M(mifepristone group), group C (control group). Main outcome measure included efficacy aspects viz mean myoma volume reduction, mean hemoglobin rise, reduction in frequency and grading symtoms. All the parameters were recorded at baseline and every 2 months till the duration of study is completed. Post treatment measurements were carried out 6 months off the drug treatment. Result: ● Mifepristone causes 46.6% reduction in fibroid volume compared to baseline(p=0.007). ● Leads to significant rise in hemoglobin and marked improvement of symptoms related to fibroid. ● Endometrial thickening was significantly increased, but none reported atypia. ● Cases in M groups reported rise in myoma size, reaching the baseline values in 6 months follow up period. Conclusion: ● Drug results in reduction in size of fibroid, but the effect is not static. ● Administering 6 months treatment with mifepristone achieves symptomatic improvement lasting upto 6 months in high percentage of cases. ● More studies need to be carried out with both the drugs for longer period of time.

Keywords: fibroid size, endometrium and symtoms.